A new study by a UCLA researcher has found no evidence to link the anti-nausea drug to an increased risk of birth defects.In fact, women with the condition who took Zofran reported fewer miscarriages and pregnancy terminations and higher live birth rates than women with extreme morning sickness who did not take the drug, said study first author Marlena Fejzo, an associate researcher in the David Geffen School of Medicine at UCLA.Many women require IV fluids and feeding tubes and are hospitalized multiple times due to the condition.In this retrospective study, data on outcomes were collected on 1,070 pregnancies exposed to Zofran and compared to outcomes in two control groups, 771 pregnancies in women with a history of HG with no Zofran exposure and 1,555 pregnancies with neither a history of HG nor Zofran exposure.Eligible patients were primarily recruited through advertising on the Hyperemesis Education and Research Foundation Web site at "This study suggests that having a history of HG, not the exposure to Zofran, may be associated with an increased risk of birth defects," Fejzo said."Women have to weigh the evidence of the efficacy of one of the most effective drugs for nausea and vomiting against the risk of birth defects.That’s definitely one of the spots – the weird little tendrils going in their weird little holes… That wasn’t scuba diving, per se, but this footage…. I don’t live in a place where scuba diving is done – D.
It’s definitely a wealthy person’s hobby, and we’re not quite there, so it takes a lot of planning.
"What was really significant to me was that women with extreme morning sickness who took Zofran reported fewer miscarriages and terminations and experienced higher live birth rates," Fejzo said.
"Taking this medication helped them get through their pregnancies and gave them their desired outcome, a live birth." This retrospective cohort study is part of a larger, ongoing investigation evaluating the genetics and epidemiology of HG.
Women suffering from extreme morning sickness often take Zofran (ondansetron) to combat their debilitating nausea and vomiting.
However, two studies have found that the drug may increase risk of heart defects and cleft palate in children exposed in utero.